Revenue
2012
2013
2014
2015
2016
2020
2021
2022
2023
2025
Crescent Biopharma, Inc. (CBIO)
Price$20.88Cached quote
Net income
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.8M | — | $10,000 | $75,000 | $1.2M | $10.2M | — | — | — | $18,500 | $20.1M | $15.0M | $4.0M | $15.3M |
| Research & development | $138.1M | $14.3M | $20.1M | $28.4M | $47.5M | $44.9M | $47.0M | $40.1M | $24.1M | $23.3M | $25.1M | $19.6M | $11.7M | $9.4M |
| Operating expenses | $163.5M | $40.0M | $39.3M | $47.5M | $64.6M | $61.7M | $61.4M | $51.5M | $33.9M | $31.9M | $32.9M | $26.2M | $14.6M | $11.6M |
| Operating income | −$152.6M | −$40.0M | −$39.3M | −$47.4M | −$63.4M | −$51.5M | −$61.4M | −$51.5M | −$33.9M | −$31.9M | −$12.8M | −$11.1M | −$10.6M | $3.6M |
| Operating margin | −1,407.52% | — | −392,752.93% | −63,204.43% | −5,470.69% | −506.84% | — | — | — | −172,505.32% | −63.70% | −74.13% | −265.65% | 23.82% |
| EBITDA | −$152.5M | −$40.0M | −$39.1M | −$47.2M | −$63.2M | −$51.2M | −$61.1M | −$51.2M | −$33.7M | −$31.7M | −$12.6M | −$11.0M | −$10.5M | $3.7M |
| EBITDA margin | −1,406.75% | — | −391,219.92% | −62,928.24% | −5,447.87% | −504.17% | — | — | — | −171,475.38% | −62.74% | −73.08% | −262.32% | 24.48% |
| Net income | −$153.9M | −$37.9M | −$36.9M | −$46.7M | −$63.4M | −$51.0M | −$57.9M | −$48.3M | −$33.3M | −$31.8M | −$12.8M | −$11.1M | −$10.6M | $3.7M |
| Net profit margin | −1,419.61% | — | −368,994.20% | −62,251.74% | −5,468.98% | −502.09% | — | — | — | −171,945.07% | −63.62% | −74.01% | −265.63% | 23.96% |
| Basic EPSper basic share | -$12.81 | -$3,717.00 | -$3,654.00 | -$5,607.00 | -$7,749.00 | -$7,056.00 | -$8,442.00 | -$7,434.00 | -$7,119.00 | -$9,450.00 | -$4,221.00 | -$3,780.00 | -$55,881.00 | $24,759.00 |
| Diluted EPSper diluted share | -$12.81 | -$3,717.00 | -$3,654.00 | -$5,607.00 | -$7,749.00 | -$7,056.00 | -$8,442.00 | -$7,434.00 | -$7,119.00 | -$9,450.00 | -$4,221.00 | -$3,780.00 | -$55,881.00 | $2,079.00 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Siren, L.L.C. / DEBBANE RAYMOND / Invus Public Equities Advisors, LLC / Invus Global Management, LLC / Invus Public Equities, L.P. | 6.32M |
FMR LLC | 4.13M |
BVF INC/IL | 2.75M |
Fairmount Funds Management LLC | 2.75M |
Venrock Adviser, LLC | 2.13M |
Logos Global Management LP | 1.9M |
FCPM III SERVICES B.V. | 1.68M |
Balyasny Asset Management L.P. | 1.66M |
Vestal Point Capital, LP | 1.63M |
Opaleye Management Inc. | 1.32M |
BlackRock, Inc. | 1.27M |
TANG CAPITAL MANAGEMENT LLC | 1.16M |
VANGUARD CAPITAL MANAGEMENT LLC | 767.76K |
MILLENNIUM MANAGEMENT LLC | 403.86K |
GEODE CAPITAL MANAGEMENT, LLC | 384.58K |
JENNISON ASSOCIATES LLC | 378.51K |
RTW INVESTMENTS, LP | 372.86K |
NEXTBio Capital Management LP | 372.86K |
Remedium Capital Partners, LLC | 361.25K |
STATE STREET CORP | 315.59K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | Lynch RyanSee Remarks | SellOrdinary Shares | 465 | $17.99 | $8.4K | 13.9K |
| Jun 22, 2026Form 4 · 10b5-1 | Pinkas JanChief Scientific Officer | SellOrdinary Shares | 1.3K | $17.99 | $23.2K | 22.2K |
| Jun 22, 2026Form 4 · 10b5-1 | Scalzo Richard WilliamChief Financial Officer | SellOrdinary Shares | 1.1K | $17.99 | $20.0K | 20.3K |
| Jun 22, 2026Form 4 · 10b5-1 | Bispham Barbara HarlinSee Remarks | SellOrdinary Shares | 1.2K | $17.99 | $21.9K | 19.3K |
| Jun 22, 2026Form 4 · 10b5-1 | Im Ellie EunkyungChief Medical Officer | SellOrdinary Shares | 1.2K | $17.99 | $21.9K | 22.1K |